Published • loading... • Updated
Low-cost B-cell depleting therapy is as effective as standard treatment for multiple sclerosis
Summary by News Medical
2 Articles
2 Articles
Low-cost B-cell depleting therapy is as effective as standard treatment for multiple sclerosis
A Norwegian Swedish clinical trial published in the New England Journal of Medicine (NEJM) demonstrates that rituximab, a low-cost B-cell depleting therapy, is as effective as ocrelizumab in newly diagnosed relapsing multiple sclerosis (MS).
·United States
Read Full Article
Patients with this medical condition of the nervous system live longer and better.
·Linz, Austria
Read Full Article
4th of July SaleGet 40% off Vantage subscriptions for yourself or a friend.Get Started
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center1Last UpdatedBias Distribution100% Center
Bias Distribution
- 100% of the sources are Center
100% Center
C 100%
Factuality
To view factuality data please Upgrade to Premium
